FAQs | How to Order | Contact Us | Prescribing Information | Important Safety Information
 Register  |  Login
             Click here to enlarge

DuoDote™ Has Replaced the Mark I™ Kit Using Next-Generation Auto-Injector Technology
DuoDote contains both atropine and pralidoxime chloride within a simple 2-in-1 auto-injector, providing an easy-to-use readiness solution for first responders in the event of a chemical nerve agent (CNA) attack or accidental exposure to organophosphorus insecticides.

Why Atropine and Pralidoxime?
This particular combination of 2 antidotes is preferred in many emergency response protocols as
well as by the U.S. military and many allied nations worldwide. [2] Please click here to learn about the complementary actions of atropine and pralidoxime chloride, and to review the history of the predecessor of DuoDote, the Mark I Kit.

Effective Against Multiple CNAs and Insecticides
Atropine and pralidoxime chloride are effective antidotes to counteract poisoning by a wide range of chemical nerve agents and organophosphorus insecticides. [1] Please click here to learn more about specific nerve agents and insecticide poisoning that can be treated with DuoDote.

The Auto-Injector Benefit
Meridian Medical Technologies is the worldwide leader in the development of auto-injector drug delivery platforms. Please click here to learn about BinaJect™, the proprietary dual-chamber technology that enables DuoDote to deliver 2 antidotes with only 1 needle and 1 injection.

Side-by-Side Comparison
DuoDote has replaced the Mark I Kit and delivers a number of additional benefits. The simplicity of a single auto-injector along with an unobtrusive, low profile design gives first responders ease of use and requires less time to administer when a rapid response is crucial. Please click here to view a side-by-side comparison with the Mark I Kit.

The DuoDote™ Auto-Injector (atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL) is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides.

IMPORTANT SAFETY INFORMATION

The DuoDote Auto-Injector is intended as an initial treatment of the symptoms of organophosphorus insecticide or nerve agent poisonings; definitive medical care should be sought immediately. The DuoDote Auto-Injector should be administered by Emergency Medical Services personnel who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication.

Individuals should not rely solely upon agents such as atropine and pralidoxime to provide complete protection from chemical nerve agents and insecticide poisoning. Primary protection against exposure to chemical nerve agents and insecticide poisoning is the wearing of protective garments including masks designed specifically for this use. Evacuation and decontamination procedures should be undertaken as soon as possible. Medical Personnel assisting evacuated victims of nerve agent poisoning should avoid contaminating themselves by exposure to the victim's clothing.

In the presence of life-threatening poisoning by organophosphorus nerve agents or insecticides, there are no absolute contraindications to the use of the DuoDote Auto-Injector. When symptoms of poisoning are not severe, DuoDote Auto-Injector should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial infarction, severe narrow angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal insufficiency, chronic pulmonary disease, or hypersensitivity to any component of the product.

Please click here to view full prescribing information for DuoDote.

Site Map | References | Copyright | Privacy Policy | Terms of Use | About Meridian


© 2007 Meridian Medical Technologies™ Inc., a subsidiary of King Pharmaceuticals®, Inc. DuoDote™ Auto-Injector, the DuoDote logo, BinaJect™, and Mark I™ Kit are trademarks of Meridian Medical Technologies™, Inc. AtroPen® is a registered trademark of Meridian Medical Technologies™, Inc. MMT 4908 10/07®